TLR7 and susceptibility to pneumonia measurement: In this context, a clinical trial for the treatment of COVID-19 pneumonia patients is currently ongoing (https://www.merckgroup.com/en/news/m5049-treatment-covid-19-pneumonia.html, accessed on 28 September 2022), and takes advantage of M5049 (from MERCK) which displays dual TLR7/8 antagonist activity.